Showing results (1-10 of 5,814) with videos related to
Sort By:
Pageof 582
Ejhaem|June 26, 2026
Sézary Syndrome: Survival Trends, Racial Disparities, and Limited Prognostic Value of Routine Registry VariablesTiantian Zhang, Weili Xue, Zhe Wang, et al.Oncotargets and Therapy|April 10, 2019
Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-γ-associated JAK-STAT pathwayWeili Xue, Weiming Li, Tiantian Zhang, et al.Cancer Biology & Medicine|February 25, 2021
Updating targets for natural killer/T-cell lymphoma immunotherapyWeili Xue, Mingzhi ZhangCancers|October 29, 2025
Circulating Tumor DNA as a Prognostic and Predictive Biomarker in Lung CancerPuneet Dhillon, Simo Du, Haiying ChengLangmuir : the ACS Journal of Surfaces and Colloids|June 20, 2020
Development of a Negative-Biased Zwitterionic Polypeptide-Based Nanodrug Vehicle for pH-Triggered Cellular Uptake and Accelerated Drug ReleaseAshish Trital, Weili Xue, Shengfu ChenInflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|October 22, 2025
Piezo1 exacerbates psoriasis by promoting macrophage M1 polarization and inhibits autophagy via activating PI3K/AKT signaling pathwayXiaoke Liu, Simo Du, Yuxiong Jiang, et al.Transplantation and Cellular Therapy|June 18, 2026
Trends and Disparities in CAR-T Therapy Utilization, Inpatient Mortality, Length of Stay, and Costs in the United States (2017-2022)Simo Du, Jiahao Peng, Tiantian Zhang, et al.Journal of Clinical Medicine|February 11, 2023
Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer TherapyTiantian Zhang, Tony Hong-Ting Jou, Jerline Hsin, et al.Langmuir : the ACS Journal of Surfaces and Colloids|November 23, 2021
Development of an Integrated High Serum Stability Zwitterionic Polypeptide-Based Nanodrug with Both Rapid Internalization and Endocellular Drug Releasing for Efficient Targeted ChemotherapyAshish Trital, Weili Xue, Longgang Wang, et al.Immunotherapy|March 13, 2019
Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapyYue Song, Zhaoming Li, Weili Xue, et al.Pageof 582